(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
30 August 2001 (30.08.2001)

PCT

(10) International Publication Number
WO 01/62246 A1

(51) International Patent Classification[7]: A61K 31/4015, A61P 25/28

(21) International Application Number: PCT/JP01/01342

(22) International Filing Date: 23 February 2001 (23.02.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
09/511,952 23 February 2000 (23.02.2000) US

(71) Applicant *(for all designated States except US)*: **DAIICHI PHARMACEUTICAL CO., LTD.** [JP/JP]; 14-10, Nihonbashi 3-chome, Chuo-ku, Tokyo 103-0027 (JP).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **OTOMO, Eiichi** [JP/JP]; 29-1, Sakuragaoka 4-chome, Tama-shi, Tokyo 206-0013 (JP). **TAKASU, Yoshiyuki** [JP/JP]; c/o DAIICHI PHARMACEUTICAL CO., LTD, Tokyo R & D Center, 16-13, Kita-Kasai 1-chome, Edogawa-ku, Tokyo 134-0081 (JP).

(74) Agents: **OGURI, Shohei** et al.; Eikoh Patent Office, 28th Floor, ARK Mori Building, 12-32, Akasaka 1-chome, Minato-ku, Tokyo 107-6028 (JP).

(81) Designated States *(national)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States *(regional)*: ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 01/62246 A1

(54) Title: METHOD FOR TREATING NEURODEGENERATION

(57) Abstract: N-(2,6-dimethylphenyl)-2-(2-oxo-1-pyrrolidinyl)acetamide is used for the preparation of medicaments, particularly of pharmaceutical compositions containing it as an active ingredient, for the treatment of neurodegeneration, in particular in post-stroke human patients. The early administration of nefiracetam in said pharmaceutical compositions after a stroke allows an improvement of the Activities of Daily Living and the recovery, or at least in improvement in the recovery of, the post-stroke patients.